Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the effects of a GLP-1 agonist on satiety hormones in patients with Prader-Willi Syndrome (genetic defect causing obesity).

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Garvan Institute of Medical Research
• Treatments: Exenatide

Criteria

Inclusion Criteria:

• see below

Exclusion Criteria:

• Diabetes mellitus, acute infections